stonks4u
Log inSign up free
MAIA logo

MAIA MAIA Biotechnology, Inc.

New York Stock Exchange Arca · Biotechnology · Healthcare

$1.35
-0.05 (-3.21%)

MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in …

Market Cap: $82.39Mwww.MAIABiotech.com

Price

No data yet.

Signal Score (90d)

80
80
Aug 17Aug 17

Quote

Day Range
$1.35 – $1.38
52-Week Range
$0.87 – $3.19
Volume
$43.5K
Market Cap
$82.39M
50-Day Avg
$1.36
200-Day Avg
$1.46
Prev Close
$1.40
Open
$1.38

Valuation & Ratios

P/E Ratio
-2.19
EPS
$-0.70
P/B Ratio
20.68
P/S Ratio
0.00
Debt/Equity
0.00
Current Ratio
1.66
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-942.7%
Return on Assets
-230.8%
FCF Yield
-38.4%
EV/EBITDA
384.39

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-22.40M$-0.70
2024$0.00$-23.25M$-1.05
2023$0.00$-19.77M$-1.49
2022$0.00$-15.77M$-1.70
2021$0.00$-12.50M$-1.18

Social Signal Score

30
5d
31
1 mentions
—
30d
30
1 mentions
—
60d
30
1 mentions
—
90d
30
1 mentions
—
news: 1

Earnings

Fri, Nov 6(in 3 months)

Consensus estimate $-0.12 per share

5of 7 quarters beat consensus

Typical surprise +15.0% (median, so one quarter with a near-zero estimate can't distort it)

  • Mon, Aug 10$-0.13 vs $-0.11miss
  • Mon, May 11$-0.14 vs $-0.18beat
  • Mon, Mar 23$-0.08 vs $-0.13beat
  • Fri, Nov 7$-0.27 vs $-0.19miss
  • Mon, Aug 11$-0.18 vs $-0.24beat
  • Fri, May 9$-0.16 vs $-0.18beat

Estimates and results for MAIA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Insider trading

Open-market buys and sells by MAIA officers and directors.

Bought
$2.4m

46 trades

Sold
—

0 trades

  • Vitoc Vladbought
    director, 10 percent owner, officer: Chief Executive Officer·72,700 @ $1.39·$101k·Jun 1, 2026·filing
  • Smith Stanbought
    director·75,000 @ $1.34·$100k·Jun 1, 2026·filing
  • Gryaznov Sergeibought
    Chief Scientific Officer·2,000 @ $1.34·$3k·Jun 1, 2026·filing
  • Smith Stanbought
    director·57,189 @ $1.22·$70k·Dec 22, 2025·filing
  • Smith Stanbought
    director·57,189 @ $1.36·$78k·Dec 22, 2025·filing
  • Chaouki Steven Mbought
    director·40,849 @ $1.22·$50k·Dec 22, 2025·filing
  • Chaouki Steven Mbought
    director·40,849 @ $1.36·$56k·Dec 22, 2025·filing
  • Louie Ngar Yeebought
    director·81,699 @ $1.22·$100k·Dec 22, 2025·filing

54 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.

Valuation

MAIAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsglobenewswire.com·6h ago·Negative

    Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) New York, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. (NYSE: MAIA). The research summary below is from a report commissioned by MAIA Biotechnology, Inc. and produced by Diamond Equity Research.

    View source ↗